These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3281057)

  • 21. [The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results].
    Acierno G
    Clin Ter; 1983 Apr; 105(2):135-45. PubMed ID: 6345054
    [No Abstract]   [Full Text] [Related]  

  • 22. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease.
    Fisman M; Mersky H; Helmes E
    Am J Psychiatry; 1981 Jul; 138(7):970-2. PubMed ID: 7020434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease.
    Kemp PM; Holmes C; Hoffmann S; Wilkinson S; Zivanovic M; Thom J; Bolt L; Fleming J; Wilkinson DG
    J Neurol Neurosurg Psychiatry; 2003 Nov; 74(11):1567-70. PubMed ID: 14617718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muscarinic agonists for senile dementia: past experience and future trends.
    Gray JA; Enz A; Spiegel R
    Trends Pharmacol Sci; 1989 Dec; Suppl():85-8. PubMed ID: 2694530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
    Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Alzheimer's disease: hopes and reality.
    Gauthier S; Gauthier L; Bouchard R; Quirion R; Sultan S
    Can J Neurol Sci; 1991 Aug; 18(3 Suppl):439-41. PubMed ID: 1933695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of cholinergic drug effects on memory in Alzheimer's disease.
    Brinkman SD; Gershon S
    Neurobiol Aging; 1983; 4(2):139-45. PubMed ID: 6355883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and tolerability of CI-979 in patients with Alzheimer's disease.
    Sramek JJ; Sedman AJ; Reece PA; Hourani J; Bockbrader H; Cutler NR
    Life Sci; 1995; 57(5):503-10. PubMed ID: 7623616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset.
    Harries MH; Samson NA; Cilia J; Hunter AJ
    Br J Pharmacol; 1998 May; 124(2):409-15. PubMed ID: 9641560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cholinergic treatment strategies in Alzheimer's disease].
    Kurz A; Rüster P; Romero B; Zimmer R
    Nervenarzt; 1986 Oct; 57(10):558-69. PubMed ID: 3785472
    [No Abstract]   [Full Text] [Related]  

  • 34. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group.
    Thal LJ; Forrest M; Loft H; Mengel H
    Neurology; 2000 Jan; 54(2):421-6. PubMed ID: 10668706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study.
    Agnoli A; Martucci N; Manna V; Conti L; Fioravanti M
    Clin Neuropharmacol; 1983; 6(4):311-23. PubMed ID: 6661730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment.
    Tsai GE; Falk WE; Gunther J; Coyle JT
    Am J Psychiatry; 1999 Mar; 156(3):467-9. PubMed ID: 10080566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.
    Mazza M; Capuano A; Bria P; Mazza S
    Eur J Neurol; 2006 Sep; 13(9):981-5. PubMed ID: 16930364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach.
    Davidson M; Stern RG
    Psychiatr Clin North Am; 1991 Jun; 14(2):461-82. PubMed ID: 2062728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease.
    Sano M; Bell K; Cote L; Dooneief G; Lawton A; Legler L; Marder K; Naini A; Stern Y; Mayeux R
    Arch Neurol; 1992 Nov; 49(11):1137-41. PubMed ID: 1444880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A bridging study of LU 25-109 in patients with probable Alzheimer's disease.
    Sramek JJ; Forrest M; Mengel H; Jhee SS; Hourani J; Cutler NR
    Life Sci; 1998; 62(3):195-202. PubMed ID: 9488097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.